摘要 |
The invention related to 4-aza-17.beta.-(cyclopropoxy)-androst-5.alpha.-androstan-3-one, 4-aza-17.beta.-(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibition of C17-20 lyase, 5.alpha.-reductase and C17.alpha.hydroxylase and to the use of these compounds in the treatment of androgen and estrogen mediated disorders, including benign prostatic hyperplasia, androgen mediated prostate cancer, estrogen mediated breast cancer and to DHT-mediated disorders such as acne. Disorders relating to the oversynthesis of cortisol, for example, Cushing's Syndrome, are also included. The treatment of androgendependent disorders also includes a combination therapy with known androgenreceptor antagonists, such as flutamide. The compounds of the invention have general formula (I).
|